Hongxia Wei
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Antifungal resistance and susceptibility
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
- Epidemiology 20
- Fungal Infections and Studies 8
- Cytomegalovirus and herpesvirus research 7
- Pneumocystis jirovecii pneumonia detection and treatment 5
-
- HIV/AIDS Research and Interventions 7
- HIV/AIDS drug development and treatment 7
- Antifungal resistance and susceptibility 5
- Co-authors
- Yuying Qiu (1 shared paper)Aiping Wang (1 shared paper)Jinan Chen (1 shared paper)Dayong Cai (1 shared paper)Hui Liao (1 shared paper)Zhiwei Hu (1 shared paper)Jing Wang (1 shared paper)Zhihong Zhang (1 shared paper)
- Journals
- Drug Discoveries & Therapeutics (2 papers)Frontiers in Public Health (2 papers)Annals of Clinical Microbiology and Antimicrobials (2 papers)Heliyon (2 papers)Clinical Infectious Diseases (1 paper)
- Partner nations
- ChinaTaiwanUnited States
In The Last Decade
Hongxia Wei
32 papers receiving 697 citations
Peers
Comparison fields: 5 of 93
- Infectious Diseases 444
- Neurology 197
- Microbiology 7
- Virology 30
- Molecular Medicine 31
Countries citing papers authored by Hongxia Wei
This map shows the geographic impact of Hongxia Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongxia Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongxia Wei more than expected).
Fields of papers citing papers by Hongxia Wei
This network shows the impact of papers produced by Hongxia Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongxia Wei. The network helps show where Hongxia Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Hongxia Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 358 | |
| 2 | 2018 | 52 | |
| 3 | 2019 | 49 | |
| 4 | 2020 | 36 | |
| 5 | 2020 | 30 | |
| 6 | 2014 | 30 | |
| 7 | 2017 | 25 | |
| 8 | 2022 | 13 | |
| 9 | 2022 | 13 | |
| 10 | 2020 | 10 | |
| 11 | 2012 | 10 | |
| 12 | 2013 | 10 | |
| 13 | 2016 | 10 | |
| 14 | 2019 | 9 | |
| 15 | 2020 | 8 | |
| 16 | 2020 | 7 | |
| 17 | [Effect of compound glycyrrhizin on peripheral T-lymphocyte subset in AIDS patients]. | 2006 | 6 |
| 18 | 2022 | 5 | |
| 19 | [Study on economic burden caused by antiretroviral treatment for people living with HIV/AIDS and influencing factors in Nanjing]. | 2015 | 4 |
| 20 | 2020 | 4 |
About Hongxia Wei
Hongxia Wei is a scholar working on Epidemiology, Infectious Diseases, Virology, Neurology and Molecular Biology, having authored 37 papers that have together received 716 indexed citations. Recurring topics across this work include Fungal Infections and Studies (8 papers), HIV/AIDS Research and Interventions (7 papers), HIV Research and Treatment (7 papers), Cytomegalovirus and herpesvirus research (7 papers), HIV/AIDS drug development and treatment (7 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers), Antifungal resistance and susceptibility (5 papers) and Long-Term Effects of COVID-19 (4 papers). The work is most often cited by research in Infectious Diseases (444 citations), Neurology (197 citations), Microbiology (7 citations), Virology (30 citations) and Molecular Medicine (31 citations). Hongxia Wei has collaborated with scholars based in China, Taiwan and United States. Frequent co-authors include Yuying Qiu, Aiping Wang, Jinan Chen, Dayong Cai, Hui Liao, Zhiwei Hu, Jing Wang, Zhihong Zhang, Tianyuan Wang and Liming Zhi. Their work appears in journals such as Drug Discoveries & Therapeutics, Frontiers in Public Health, Annals of Clinical Microbiology and Antimicrobials, Heliyon and Clinical Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.